Psilocybin and MAOIs: Why This Combination Can Be Dangerous
MAOIs are not just another antidepressant class in the psilocybin interaction table. They can slow psilocin breakdown, intensify the experience, and extend its duration. This page explains why the combination is treated as a hard stop in harm-reduction guidance.
Published
Chief Bear · ~8 min read
Quick Answer
Do not combine psilocybin with MAOIs. MAOIs can prevent normal psilocin breakdown, making the experience stronger, longer, and harder to manage. The main concerns are overwhelming psychological intensity, blood-pressure reactions, and theoretical serotonin toxicity. If you take an MAOI, talk with the prescribing clinician before considering any psychedelic.
At-a-Glance Risk Table
| MAOI type | Examples | Psilocybin risk |
|---|---|---|
| Irreversible MAOIs | Phenelzine, tranylcypromine, isocarboxazid | Avoid Strong and prolonged potentiation risk. |
| Reversible MAOIs | Moclobemide | Avoid Shorter acting, but still directly relevant. |
| Selective MAO-B inhibitors | Selegiline, rasagiline | Caution Higher doses lose selectivity and become riskier. |
| Harmala alkaloids | Syrian rue, Banisteriopsis caapi extracts | Avoid Deliberate potentiation outside clinical care is unpredictable. |
Why MAOIs Change a Psilocybin Experience
After ingestion, psilocybin is converted into psilocin. Psilocin acts mainly at serotonin 5-HT2A receptors, then the body clears it through several routes, including monoamine oxidase and glucuronidation. MAOIs block part of that clearance pathway. The result can be higher psilocin exposure, a longer session, and a steeper psychological curve than the dose would normally produce.
That is why the risk is different from SSRI blunting. SSRIs usually reduce psilocybin intensity by downregulating the target receptor over time. MAOIs can move in the opposite direction: they may make psilocybin more intense and prolonged. In a supervised medical trial, dose, monitoring, and rescue medication are planned. In a self-directed setting, the same potentiation is a safety problem.
Medication Examples to Recognize
Prescription MAOIs are less common than SSRIs, but they still matter because people who take them often have complex depression histories. Examples include phenelzine, tranylcypromine, isocarboxazid, selegiline patches, and moclobemide where available. Some non-prescription products also inhibit monoamine oxidase, including Syrian rue and other harmala-containing preparations.
If a medication guide says “MAOI,” “monoamine oxidase inhibitor,” “MAO-A,” “MAO-B,” “serotonin syndrome warning,” or “avoid tyramine,” treat it as relevant to psilocybin until a clinician tells you otherwise.
Why “But Ayahuasca Uses MAOIs” Is Not the Same Thing
Traditional ayahuasca combines DMT-containing plants with plants that contain reversible MAO inhibitors. That does not make MAOI combinations generally safe. It means that one tradition uses a specific pharmacological interaction with its own dosing customs, screening norms, and risks.
Applying the same principle casually to psilocybin can produce a session that lasts longer than expected, becomes psychologically overwhelming, or collides with other medications. PsyBear’s guidance is conservative: do not use MAOIs to “boost” mushrooms, and do not combine prescription MAOIs with psilocybin outside a legitimate medical or research protocol.
What to Ask a Prescriber
- Is my medication an MAOI, MAO-B inhibitor, or mixed serotonergic drug?
- What is the safest washout timeline for this specific medication?
- What symptoms should I monitor if a taper is clinically appropriate?
- What is the relapse plan if depression, anxiety, or suicidality returns during washout?
- Is psilocybin therapy appropriate for my diagnosis, or are there screening red flags?
Key Takeaways
- MAOIs are a do-not-combine class for psilocybin because they can intensify and prolong psilocin exposure.
- This is different from SSRI blunting. MAOIs may amplify; SSRIs usually dampen.
- Washout timing is medication-specific and should be managed by the prescriber, not guessed.
- The ayahuasca analogy does not make casual MAOI potentiation safe.